Author

Larisa Strom

Institutions: National Institutes of Health, National Institute of Allergy and Infectious Diseases, Vaccine Research Center

Observed institutions: National Institutes of Health, Colorado School of Public Health, Peking University, Society of Critical Care Medicine, University of Alabama at Birmingham, Massachusetts General Hospital, National Institute of Allergy and Infectious Diseases, UAB Medicine, Vaccine Research Center, Walter Reed Army Institute of Research

OpenAlex ID: A5104074693

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

2022 · Katherine V. Houser, Grace L. Chen, et al. · Nature Medicine · 164

PDF

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

2022 · Richard L. Wu, Azza H. Idris, et al. · New England Journal of Medicine · 122

PDF

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

2023 · Alicia T. Widge, Amelia R. Hofstetter, et al. · Science Translational Medicine · 96

PDF

Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19

2021 · Joshua L. Denson, Aaron S. Gillet, et al. · JAMA Network Open · 84

PDF

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

2023 · Melinda J Hamer, Katherine V Houser, et al. · The Lancet · 68

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial

2023 · Kirsten E Lyke, Andrea A Berry, et al. · The Lancet Infectious Diseases · 45

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

2022 · Katherine V. Houser, Martin R. Gaudinski, et al. · EClinicalMedicine · 41

Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

2022 · Emily E Coates, Srilatha Edupuganti, et al. · The Lancet Infectious Diseases · 41

Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

2023 · Betty Mwesigwa, Katherine V Houser, et al. · The Lancet Infectious Diseases · 27

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

2024 · Joseph P. Casazza, Amelia R. Hofstetter, et al. · npj Vaccines · 25

PDF

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

2024 · Myra Happe, Amelia R. Hofstetter, et al. · npj Vaccines · 21

PDF

Clonal hematopoiesis is not significantly associated with COVID-19 disease severity

2022 · Yifan Zhou, Ruba Shalhoub, et al. · Blood · 21

PDF

Gastrointestinal Manifestations in Hospitalized Children With Acute SARS-CoV-2 Infection and Multisystem Inflammatory Condition: An Analysis of the VIRUS COVID-19 Registry

2022 · Imran A. Sayed, Utpal Bhalala, et al. · The Pediatric Infectious Disease Journal · 17

Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection

2025 · Myra Happe, Rebecca M. Lynch, et al. · JCI Insight · 11

SARS-CoV-2 infection increases risk of acute kidney injury in a bimodal age distribution

2022 · Erica C. Bjornstad, Gary Cutter, et al. · BMC Nephrology · 10

PDF

Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults

2025 · Richard L Wu, Katherine V Houser, et al. · The Lancet HIV · 9

Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS

2024 · Seemal F. Awan, Amarendra Pegu, et al. · JCI Insight · 7

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial

2026 · Aurélie Ploquin, Rosemarie D. Mason, et al. · Nature Medicine · 6

PDF

Association of Early Steroid Administration With Outcomes of Children Hospitalized for COVID-19 Without Multisystem Inflammatory Syndrome in Children

2022 · Sandeep Tripathi, Meghana Nadiger, et al. · Archives of Pediatrics and Adolescent Medicine · 5

PDF

Optimization of the CIS43LS Malarial Monoclonal Antibody and Protection Against Malaria

2022 · Kirsten E. Lyke, Andrea A. Berry, et al. · SSRN Electronic Journal

Works count: 20

Citation count: 820

H-index: 13

I10-index: 15